Post-Brexit device rules risk the UK falling behind
The new regulatory scheme poses problems – but also opportunities, in the shape of possible alignment with the US.
Ionis joins the inhaled cystic fibrosis therapy race
Ionis’s inhaled antisense candidate shows promising signs, with Arrowhead and Translate Bio also in the running.
J&J and Novavax push Covid-19 vaccine candidates into late-stage testing
Five candidates are now in phase III trials in the West, as Pfizer approaches its first interim readout.
Semorinemab failure tempers tau hopes
The next big approach in Alzheimer’s has been dealt a blow, and there are plenty more tau-targeting contenders.
With its liquid biopsy approval, Foundation Medicine takes on Guardant
The first pan-cancer approval might have gone to Guardant, but Roche’s subsidiary’s blood test appears to be able to find more markers.
How best to develop a liquid biopsy?
Natera’s cancer blood test is couture, but Guardant’s pret-a-porter offering might sell better.
Medtech venture backers play it safe
Liquid biopsy developer Grail exemplifies 2020’s trend of sizeable mid-stage financings.
Covid-19 antibody tests face a very specific problem
With the prevalence of coronavirus infection running at about 5%, test manufacturers and regulators alike will have to guard against false positives.
Joint makers report pandemic pain
Sales of implants are set to fall sharply as non-urgent procedures are deferred.
